Genome Editing/Genome Engineering Market was valued at over US$ 3.0 Bn. in 2017 and is anticipated to grow at a CAGR of 14.1% from 2019 to 2030.
The growth of this market can be attributed to the major factor that is utilization of the technique for therapeutic genetic editing in infected tissues and cells, thereby reducing the mutations.
Major Key Players of the Genome Editing/Genome Engineering Market are:
Thermo Fisher Scientific, Lonza, Merck, Horizon Discovery Group, Integrated DNA Technologies, New England Biolabs (US), GenScript (US), Sangamo BioSciences (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland)., among others.
No comments:
Post a Comment